Mineralys Therapeutics, Inc. Common Stock (MLYS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.29B
Last updated: Nov 17, 2026 at 4:15 PM ET
Mineralys Therapeutics, Inc. Common Stock (MLYS) Statistics
Mineralys Therapeutics, Inc. Common Stock (MLYS) has a market cap of $1.29B and an enterprise value of $1.28B. Its share count is up 26.05% from a year earlier. Revenue fell 100.00% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 0.23% below the market cap, as cash exceeds debt.
| Market Cap | $1.29B |
|---|---|
| Enterprise Value | $1.28B |
| Latest price (Nov 17, 2026) | $14.48 |
Key Dates
The next earnings report is expected on Mar 10, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 10, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 4, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is down 64.55% over 52 weeks and trades 34.33% below its 50-day average.
| Beta (1Y) | 1.62 |
|---|---|
| 52-Week Change | -64.55% |
| 1-Month Change | -30.78% |
| 3-Month Change | -46.27% |
| 6-Month Change | -44.37% |
| Total Return (1Y) | -64.55% |
| Total Return (3Y CAGR) | +28.46% |
| Return vs SPY (1Y) | -78.19% |
| Max Drawdown (1Y) | -67.28% |
| Max Drawdown (3Y) | -69.41% |
| Sharpe Ratio (1Y) | -1.81 |
| Correlation with SPY (1Y) | 0.37 |
| 50-Day Average | $22.05 |
| 200-Day Average | $25.99 |
| 52-Week Range | $14.45 to $44.99 |
| RSI (14 Days) | 29.5 |
| Average Volume (20 Days) | 2.01M |
Financial Position
Current assets cover 11.83x current liabilities, and total debt is 0.20x shareholder equity.
| Current Ratio | 11.83x |
|---|---|
| Quick Ratio | 11.83x |
| Debt / Equity | 0.20x |
Returns and Efficiency
Return on invested capital is -51.14% and return on equity is -73.44% over the last 12 months.
| Return on Equity (ROE) | -73.44% |
|---|---|
| Return on Assets (ROA) | -58.71% |
| Return on Invested Capital (ROIC) | -51.14% |
| ROA (5Y Average) | -67.76% |
Scores
MLYS has a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 3 of 9 |
|---|---|
| Piotroski Strength | Average |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Revenue Growth (YoY) | -100.00% |
| Gross Profit | -$13.00K |
| Operating Income | -$389.75M |
| Pretax Income | -$369.97M |
| Net Income | -$369.97M |
| Reported EPS (TTM) | -$4.36 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 79.95% of the $630.12M in total assets.
| Cash and Equivalents | $101.27M |
|---|---|
| Total Debt | $98.27M |
| Net Cash | $3.00M |
| Net Cash Per Share | $0.03 |
| Working Capital | $574.92M |
| Shareholder Equity | $503.77M |
| Book Value Per Share | $5.66 |
| Total Assets | $630.12M |
| Total Liabilities | $126.35M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$153.01M |
|---|---|
| FCF Per Share | -$1.73 |
| Depreciation and Amortization | $17.53M |
Trailing 12 months through Sep 30, 2026.
Growth
| Book Value Per Share Growth (2Y CAGR) | +15.54% |
|---|---|
| Tangible Book Per Share Growth (2Y CAGR) | +15.54% |
Dividends and Yields
MLYS does not pay a dividend.
| Buyback Yield | -19.85% |
|---|---|
| Shareholder Yield | -19.85% |
Peer Position
Against 4 similar companies, MLYS has the highest ROIC.
ROICPeer median -65.50%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +12.71%
| ROIC | -51.14% vs -65.50% median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | -100.00% vs +12.71% median |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About MLYS
What is MLYS's market cap?
Mineralys Therapeutics, Inc. Common Stock has a market cap of $1.29B. Its enterprise value, which adds debt and subtracts cash, is $1.28B.
How many shares of MLYS are outstanding?
Mineralys Therapeutics, Inc. Common Stock has 88.99M shares outstanding. The count is up 26.05% from a year earlier.
Does MLYS pay a dividend?
No. Mineralys Therapeutics, Inc. Common Stock does not pay a dividend.
How much debt does MLYS have?
Mineralys Therapeutics, Inc. Common Stock has $98.27M of total debt and $101.27M of cash and equivalents, a net cash position of $3.00M.
MLYS pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors